Skip to main content
. Author manuscript; available in PMC: 2014 Oct 15.
Published in final edited form as: Adv Drug Deliv Rev. 2012 Aug 17;65(10):1331–1339. doi: 10.1016/j.addr.2012.07.012

Figure 1.

Figure 1

A schematic presentation of the hydrophobic and electrostatic interactions involved in fatty acid-albumin binding (A). The addition of a drug, or surrogate such as fluoresceinamine (blue), may utilize only the hydrophobic interaction (B) or both hydrophobic and electrostatic (red) interactions (C) depending on the modification chemistry.